


What is claimed is

1. A compound according to Formula I herein below:



Formula (I)

wherein:

R^1 is selected from the group consisting of a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-4} alkyl, C_{1-4} alkoxy, aryl C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkoxy C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, C_{1-4} alkylsulfonyl, C_{1-4} alkylsulfonyloxy, C_{1-4} alkylsulfonyl C_{1-4} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-4} alkyl, C_{1-4} alkylsulfonamido, C_{1-4} alkylamido, C_{1-4} alkylsulfonamido C_{1-4} alkyl, C_{1-4} alkylamido C_{1-4} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-4} alkyl or a arylcarboxamido C_{1-4} alkyl group; a group $R^3OCO(CH_2)_p$, $R^3CON(R^4)(CH_2)_p$, $R^3R^4NCO(CH_2)_p$ and $R^3R^4NSO_2(CH_2)_p$, where each of R^3 and R^4 is, independently, selected from a group consisting of a hydrogen atom and a C_{1-4} alkyl group or R^3R^4 forms part of a C_{3-6} azacycloalkane or $C_{3-6}(2\text{-oxo})$ azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar^3-Z , wherein Ar^3 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring and Z represents a bond, O, S, or CH_2 ;


R^2 is selected from a group consisting of a hydrogen atom or a C_{1-4} alkyl group;

q is 1 or 2;


A is selected from the group consisting of a group of the formula (a), (b) (c) and (d):




(a)



(b)



(c)



(d)

wherein

Ar is selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system;

Ar¹ and Ar² each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and

Y is selected from a group consisting of a bond, -NHCO-, -CONH-, -CH₂-, or -(CH₂)_mY¹(CH₂)_n-, wherein Y¹ represents O, S, SO₂, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1; providing that when A represents a group of formula (a), any substituent present in Ar *ortho* to the carboxamide moiety is necessarily a hydrogen or a methoxy group;

r and s are, independently, selected from a group consisting of an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 4; and

V is selected from a group consisting of a bond, O or S;

and salts thereof.

2. A compound according to claim 1 consisting of the group selected from:
 - trans*-3-(2-(1-(4-(4-Quinoliny)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
 - trans*-(*E*)-3-(2-(1-(4-(3-(3-Methylsulfonyl)phenylpropenoyl) amino) cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
 - trans*-(*E*)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
 - trans*-3-(2-(1-(4-(2-Indolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
 - trans*-3-(2-(1-(4-(3-(3-Pyridyl)phenyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
 - trans*-3-(2-(1-(4-Phenylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-3-(2-(1-(4-(3-Indolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-3-(2-(1-(4-(4-Quinoliny)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-6-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-6-Methoxy-3-(2-(1-(4-(4-quinoliny)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-6-Methoxy-3-(2-(1-(4-(3-pyrrolo[2,3-*b*]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-methyl)-1,2,4-oxadiazolyl)benzoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-acetylamino)phenylpropenoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-3-oxo)-2*H*-benzoxazinyl)carboxamido)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(6-(1,2-dihydro-2-oxo)quinoliny)propenoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-4-acetylamino)phenylpropenoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(8-(1,2-dihydro-2-oxo)quinoliny)propenoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-3-(2-(1-(4-(3-(3-(5-Methyl)-1,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-*b*]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido)

cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(2,5-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2,4-difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2,5-difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-phenylpropanoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)isoxazolyl)benzoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*Z*)-7-Cyano-3-(2-(1-(4-(3-phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-pyridyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(1-(4-fluoro)naphthyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(6-benzodioxanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-(5-fluoro)indolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-(1-methyl)benzimidazolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(7-benzofuranyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)indolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(6-(2,3-dihydro-2-oxo)indolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(2-benzofuranylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-(2-methyl)indolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(5-benzimidazolyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2,3-methylenedioxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-(1-(2-oxo)pyrrolidinyl))phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(2-indolylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(2-benzothiophenylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-(3-bromo)thiophenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(3-(2-pyridyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(3-(4-cyanophenyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-thiophenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-furanyl)propenoyl)amino)

cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-thiophenyl)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-furanyl)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-quinoliny)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(2,4-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5-
tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-(2-methyl)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(4-methylaminocarbonyl)phenylpropenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(5-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(1-pyrazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-
tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(2-thiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-
tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-benzothiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-
tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(2-(5-methyl)-1,3,4-oxadiazolyl)benzoyl)amino)-
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-naphthyl)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(5-(3-acetyl)indolyl)propenoyl)amino)
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)-1,2,4-oxadiazolyl)benzoyl)amino)-
cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(5-(2-methyl)benzimidazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-(2-acetyl)furanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinoliny)l)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-(5-Methyl)-1,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(8-(1,4-dihydro-4-oxo)quinoliny)l)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-acetamido-2-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-(*E*)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2,4-difluoro)phenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2-naphthyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(7-(3,4-dihydro-3-oxo)-2*H*-benzoxazinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2-fluoro)phenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-3-(2-(1-(4-(5-(2-Methyl)quinoliny)l)carboxamide)cyclohexyl)ethyl)-7-methanesulphonyloxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2-indolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-*b*]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(8-(1,4-dihydro-4-oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-(5-Methyl)-1,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(2-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(2-fluoro)phenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(4-fluoro)phenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(2-(5-Methyl)oxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(5-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(5-Pyrimidinyl)-3-(2-(1-(4-(3-(3-(5-Methyl)-1,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and
trans-3-(2-(1-(4-(3-(2-(5-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyloxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

3. A compound according to claim 1 consisting of the group selected from:
trans-7-Cyano-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(2-naphthylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(8-(1,4-dihydro-4-oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(3-methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(7-(1,2-dihydro-2-oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-ethyl)-1,2,4-oxadiazolyl)benzoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(1-naphthyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(5-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-(1,2-dihydro-2-oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-7-Cyano-3-(2-(1-(4-(7-(1,2-dihydro-2-oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-quinoxaliny)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-2-oxo)-2*H*-benzoxazinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-5-acetamido)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(3-(2-(4-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(3-trifluoromethylbenzoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(5-Pyrimidinyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(3-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and
trans-(*E*)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

4. A compound according to claim 1 selected from the group consisting of:
trans-(*E*)-7-Cyano-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(5-(8-fluoro)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7-methanesulphonyloxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

trans-3-(2-(1-(4-(5-(8-Chloro-2-methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7-methanesulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(2-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-(*E*)-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-pyrrolo[2,3-*b*]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
trans-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7-methylsulphonyloxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

5. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.

6. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.

7. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.

8. A method according to claim 7 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.

9. A method according to claim 8 wherein administration is via inhalation via the mouth or nose.

10. A method according to claim 9 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
11. A method according to claim 10 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
12. A method according to claim 11 wherein the compound has a duration of action of 24 hours or more.
13. A method according to claim 12 wherein the compound has a duration of action of 36 hours or more.